newsfilter
← Latest News
GlobeNewswire·

Prometheus Biosciences Announces Initiation of APOLLO-CD Phase 2a Clinical Trial of PRA023 in Moderate-to-Severe Crohn's Disease

- First Anti-TL1A trial in Crohn's Disease - - APOLLO-CD Phase 2a along with ARTEMIS-UC Phase 2 topline results expected in fourth quarter 2022 - - Final Phase 1a results for PRA023 in normal healthy volunteers expected in fourth quarter 2021- S